MIRA

MIRA Pharmaceuticals, Inc. (MIRA) ESG Analysis Analysis (2026)

Invetso Score: 5.7/10 — Balanced · Last Updated: 2026-09-01

Environmental

No disclosed environmental metrics in the provided filings data limit direct peer comparison, leaving positioning broadly neutral versus similarly opaque peers.

Zero reported R&D intensity suggests limited evidence of climate-linked product or process investment, which is weaker than peers with disclosed transition spending.

The absence of reported environmental disclosures reduces transparency on emissions, energy, and waste management, creating a disclosure gap versus better-reporting peers.

No provided data indicate material environmental controversies or regulatory breaches, so the company does not appear structurally worse than peers on known environmental risk.

Social

No provided workforce, safety, or human-capital metrics constrain assessment, so social positioning remains difficult to distinguish from peers with fuller disclosure.

Zero stock-based compensation to revenue suggests limited dilution pressure, but it does not materially evidence stronger employee alignment than peers.

The lack of disclosed social indicators on turnover, diversity, or labor practices weakens transparency relative to peers that report these metrics consistently.

No supplied evidence points to major labor or product-safety controversies, keeping social risk broadly in line with peers rather than clearly advantaged.

Governance

A net debt to EBITDA ratio of 0.38 indicates conservative leverage, which is generally stronger than more indebted peers on balance-sheet discipline.

Zero debt-to-equity suggests limited structural leverage risk, supporting governance resilience relative to peers with heavier financing dependence.

No provided data show elevated stock-based compensation, which can reduce dilution concerns and compares favorably with peers using more aggressive equity pay.

Limited disclosure on board independence, audit quality, and shareholder rights prevents a stronger governance score despite the favorable leverage profile.

Overall Score

MIRA’s ESG positioning is broadly average versus peers, with relatively stronger governance discipline offset by limited environmental and social disclosure.

Score Driver: Conservative Leverage And Low Dilution Risk Support Governance, But Sparse ESG Disclosure Keeps The Overall Profile Only Moderately Positioned Versus Peers.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on MIRA Pharmaceuticals, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →